Should I buy or sell TransMedics Group stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks .

What is TransMedics Group's stock price target for 2024?

7 brokerages have issued twelve-month price objectives for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $110.00. On average, they expect the company's stock price to reach $102.00 in the next year. This suggests a possible upside of 22.8% from the stock's current price. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts .

How have TMDX shares performed in 2024?

TransMedics Group's stock was trading at $78.93 at the start of the year. Since then, TMDX stock has increased by 5.2% and is now trading at $83.07. View the best growth stocks for 2024 here .

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our TMDX earnings forecast .

How can I listen to TransMedics Group's earnings call?

TransMedics Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, February, 26th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 2.35%. TransMedics Group's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) earnings per share.

What ETFs hold TransMedics Group's stock?

ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE) , Clough Long/Short Equity ETF (CBLS) , Innovator IBD 50 ETF (FFTY) , SPDR S&P Health Care Equipment ETF (XHE) , BNY Mellon Innovators ETF (BKIV) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com . Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD) , Roku (ROKU) , AbbVie (ABBV) , Gilead Sciences (GILD) , Pfizer (PFE) , RTX (RTX) , Yamana Gold (AUY) , B2Gold (BTG) , Beyond Meat (BYND) and Walt Disney (DIS) .

When did TransMedics Group IPO?

TransMedics Group (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.23%), Wasatch Advisors LP (1.33%), Park Avenue Securities LLC (0.03%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr , James R Tobin, John F Carey , Laura Damme , Miriam Provost , Stephanie Lovell, Stephen Gordon , Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein . View institutional ownership trends .

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free TMDX Stock Alerts

$84.16

-3.08 (-3.53%)

(As of 05:21 PM ET)

Compare

Today's Range: $82.87
▼
$88.75
50-Day Range: $70.86
▼
$95.65
52-Week Range: $36.42
▼
$99.63

Volume: 957,643 shs
Average Volume: 692,512 shs
Market Capitalization: $2.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $102.00

Get TransMedics Group alerts:

TransMedics Group MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 22.8% Upside
$102.00 Price Target
Short Interest: Bearish
18.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 12 Articles This Week
Insider Trading: Selling Shares
$10.18 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.14) to $0.41 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.76 out of 5 stars

Medical Sector

837th out of 918 stocks

Electromedical Equipment Industry

17th out of 19 stocks

2.4

Analyst's Opinion

Consensus Rating
TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
TransMedics Group has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
18.31% of the outstanding shares of TransMedics Group have been sold short.
Short Interest Ratio / Days to Cover
TransMedics Group has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in TransMedics Group has recently increased by 10.72%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TransMedics Group does not currently pay a dividend.
Dividend Growth
TransMedics Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TMDX.

1.8

News and Social Media Coverage

News Sentiment
TransMedics Group has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for TransMedics Group this week, compared to 4 articles on an average week.
Search Interest
Only 13 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
MarketBeat Follows
Only 11 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,182,881.00 in company stock.
Percentage Held by Insiders
Only 6.70% of the stock of TransMedics Group is held by insiders.
Percentage Held by Institutions
99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for TransMedics Group are expected to grow in the coming year, from ($0.14) to $0.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TransMedics Group is -107.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TransMedics Group is -107.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TransMedics Group has a P/B Ratio of 19.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About TransMedics Group Stock (NASDAQ:TMDX)

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TMDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TMDX Stock News Headlines

April 19, 2024 | insidertrades.com

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares

April 14, 2024 | insidertrades.com

Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of Stock

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 11, 2024 | insidertrades.com

Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of Stock

April 6, 2024 | insidertrades.com

TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in Stock

April 3, 2024 | insidertrades.com

Stephen Gordon Sells 15,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

April 18, 2024 | americanbankingnews.com

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from Brokerages

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - TMDX

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 16, 2024 | finance.yahoo.com

TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024

April 15, 2024 | finance.yahoo.com

There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital

April 12, 2024 | investorplace.com

Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024

April 12, 2024 | investing.com

TransMedics group exec sells over $1.79 million in company stock

April 12, 2024 | investorplace.com

3 Must-Own Stocks for Sustained Growth Over the Next 18 Months

April 12, 2024 | americanbankingnews.com

Tamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

April 11, 2024 | investorplace.com

The 3 Most Promising MedTech Stocks to Invest In Now

April 11, 2024 | finance.yahoo.com

Heart And Lung Transplants Drive Medical Stock Higher As S&P 500 Fizzles

April 11, 2024 | investors.com

Organ Transplant Stock Surges Past Buy Point Even As S&P 500 Fizzles

April 8, 2024 | prnewswire.com

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 25, 2024 | markets.businessinsider.com

TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating

March 22, 2024 | seekingalpha.com

TransMedics: Strong Business, Fully Valued Stock

March 19, 2024 | finance.yahoo.com

TMDX Jul 2024 135.000 call

March 12, 2024 | seekingalpha.com

TransMedics Group: Huge Opportunity In Organ Transplants

March 5, 2024 | finance.yahoo.com

Jim Cramer’s Latest Lightning Round: 11 Stock Recommendations

March 3, 2024 | markets.businessinsider.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX

March 3, 2024 | finance.yahoo.com

Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts

March 3, 2024 | fool.com

2 No-Brainer Growth Stocks to Buy With $100 in March

See More Headlines

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:TMDX
CUSIP: N/A
CIK: 1756262
Web: www.transmedics.com
Phone: (978) 552-0900
Fax: N/A
Employees: 584
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $102.00
High Stock Price Target: $110.00
Low Stock Price Target: $95.00
Potential Upside/Downside: +22.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,030,000.00
Net Margins: -10.36%
Pretax Margin: -11.04%
Return on Equity: -2.35%
Return on Assets: -0.60%

Debt

Debt-to-Equity Ratio: 3.69
Current Ratio: 9.30
Quick Ratio: 8.49

Sales & Book Value

Annual Sales: $241.62 million
Price / Sales: 11.28
Cash Flow: $0.13 per share
Price / Cash Flow: 617.26
Book Value: $4.20 per share
Price / Book: 19.84

Miscellaneous

Outstanding Shares: 32,710,000
Free Float: 30,521,000
Market Cap: $2.73 billion
Optionable: Optionable
Beta: 1.99

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Waleed H. Hassanein M.D. (Age 56)
Founder, President, CEO & Director
Comp: $1.82M
Mr. Stephen Gordon (Age 56)
CFO, Treasurer & Secretary
Comp: $909.62k
Mr. Mark Anderson
Senior Director of Technology Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.
What is TransMedics Group's stock price target for 2024?: 7 brokerages have issued twelve-month price objectives for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $110.00. On average, they expect the company's stock price to reach $102.00 in the next year. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.
How have TMDX shares performed in 2024?: TransMedics Group's stock was trading at $78.93 at the start of the year. Since then, TMDX stock has increased by 5.2% and is now trading at $83.07.
View the best growth stocks for 2024 here.
When is TransMedics Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our TMDX earnings forecast.
How can I listen to TransMedics Group's earnings call?: TransMedics Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were TransMedics Group's earnings last quarter?: TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, February, 26th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 2.35%. TransMedics Group's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) earnings per share.
What ETFs hold TransMedics Group's stock?: ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), BNY Mellon Innovators ETF (BKIV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Principal Healthcare Innovators ETF (BTEC).

What guidance has TransMedics Group issued on next quarter's earnings?: TransMedics Group updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million.
What is Waleed Hassanein's approval rating as TransMedics Group's CEO?: 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.
What other stocks do shareholders of TransMedics Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).
When did TransMedics Group IPO?: TransMedics Group (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.
Who are TransMedics Group's major shareholders?: TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.23%), Wasatch Advisors LP (1.33%), Park Avenue Securities LLC (0.03%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends.
How do I buy shares of TransMedics Group?: Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMDX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial